What is Jackson ImmunoResearch?
Jackson ImmunoResearch operates as a specialized manufacturer of secondary antibodies and high-performance reagents, serving as a cornerstone for laboratories engaged in complex biophysical and biochemical research. The company's product portfolio, which includes essential tools for ELISA, Western blotting, and FACS, is recognized for its rigorous consistency and stability. By providing high-quality reagents to research institutions and academic centers, Jackson ImmunoResearch facilitates precision in experimental outcomes, effectively bridging the gap between raw biological data and actionable scientific discovery. Their commitment to technical reliability has established them as a trusted partner in the life sciences ecosystem.
How much funding has Jackson ImmunoResearch raised?
Jackson ImmunoResearch has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Jackson ImmunoResearch
PPP
Public-Private Partnership
What's next for Jackson ImmunoResearch?
With the recent influx of capital, Jackson ImmunoResearch is poised to scale its manufacturing infrastructure to meet the rising demand for high-purity reagents. The strategic roadmap likely involves enhancing technical support capabilities and optimizing supply chain logistics to maintain their competitive edge in the global market. As the company transitions into this next phase of growth, the focus will remain on sustaining product excellence while exploring new applications for their antibody technology in emerging diagnostic and therapeutic research fields. This financial backing provides the necessary runway to innovate within the reagent space and solidify their status as a leader in laboratory-grade biochemical solutions.
See full Jackson ImmunoResearch company page
